PrimeRFP SCOUT · Federal Contract Recompete Brief

36C25224F0044Gozetotide radiopharmaceutical — Telix Pharmaceuticals (Us) Inc

Telix Pharmaceuticals (Us) Inc holds $6.9M across 17 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 1 related award under parent 36F79722D0197. Competition previously drew 3 offers. PoP ended Nov 30, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

252-Network Contract Office 12 (36C252)

Awarding office

Telix Pharmaceuticals (Us) Inc

Recipient

Nov 30, 2024

PoP end

$245K

Obligated

$245K

Potential

325412

NAICS

6505

PSC

3 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Telix Pharmaceuticals (Us) Inc — $90

Contract facts

Federal

Contract number36C25224F0044

Also listed as36C252-24-F-0044

Also listed as36F79722D0197-36C25224F0044

Agency252-Network Contract Office 12 (36C252)

Awarding office252-Network Contract Office 12 (36C252)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentTelix Pharmaceuticals (Us) Inc

CAGE8CP27

UEINMRHMBK4YTH7

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79722D0197

Place of performanceNORCROSS GA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startDec 1, 2023

PoP end (current)Nov 30, 2024

Obligated$245K

Current value$245K

Potential value$245K

GOZETOTIDE RADIOPHARMACEUTICAL is a federal award for 252-Network Contract Office 12 (36C252) held by Telix Pharmaceuticals (Us) Inc. Estimated value $245K ($245K obligated). Current period of performance ends Nov 30, 2024. Last award drew 3 bidders. Place of performance: NORCROSS GA.

Recompete timing

Public

● Past PoP end (629 days ago)

Current PoP ended Nov 30, 2024 (629 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Telix Pharmaceuticals (Us) Inc — $6.9M obligated across 17 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)

Department of Veterans Affairs (VA)$6.9M · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

36C24826N0054

ILLUCCIX

$1.8M

Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C25224F0044?

36C25224F0044 (Gozetotide radiopharmaceutical) is a 252-Network Contract Office 12 (36C252) award with a potential value of $245K, currently held by Telix Pharmaceuticals (Us) Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C252-24-F-0044?

36C252-24-F-0044 is the dashed form of PIID 36C25224F0044 (Gozetotide radiopharmaceutical), held by Telix Pharmaceuticals (Us) Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C25224F0044?

252-Network Contract Office 12 (36C252) awarded 36C25224F0044 to Telix Pharmaceuticals (Us) Inc (potential $245K).

Who is the incumbent on 36C25224F0044?

Telix Pharmaceuticals (Us) Inc is the incumbent with $6.9M across 17 related awards in SCOUT’s public footprint. The current period of performance ends Nov 30, 2024.

When does Telix Pharmaceuticals (Us) Inc’s 36C25224F0044 come up for recompete?

SCOUT tracks a period-of-performance end of Nov 30, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 26, 2026 · refreshed monthlyLatest procurement action Nov 30, 2023